China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Receivables - Other for 9 consecutive years, with $15.8 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Other rose 3694.78% year-over-year to $15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.8 million (up 3694.78% YoY) and the FY2026 annual result came in at $15.8 million, up 3694.78% from the prior year.
• Receivables - Other rose to $15.8 million in Q1 2026 per SXTC's latest filing, from $1.4 million in the prior quarter.
• Over the last five years, Receivables - Other for SXTC reached as high as $15.8 million in Q1 2026 and fell as low as $83634.0 in Q1 2024.
• A 5-year average of $2.8 million and a median of $839314.0 in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other sank 63.74% — and 2026, when it soared 3694.78%.
• Year by year, Receivables - Other stood at $2.7 million in 2022, then tumbled by 91.61% to $230642.0 in 2023, then jumped by 378.17% to $1.1 million in 2024, then rose by 23.72% to $1.4 million in 2025, then jumped by 1061.33% to $15.8 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $15.8 million, $1.4 million, and $417563.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.